Who
Justin A. Renz
CFO
Company insider
Files Form 4 as: CFO, Zevra Therapeutics; Chief Financial Officer, Ardelyx; EVP, CFO & Treasurer, Karyopharm Therapeutics; EVP, CFO & Treasurer, Zalicus.
In numbers
- Trades disclosed
- 68
- Buys
- 2
- Sells
- 23
- Bought
- $150K
- Sold
- $1.8M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 21 Dec 2009
- Last trade
- 18 Mar 2026
- Last filed
- 19 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Mar 2026filed 19 Mar 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 18 Mar 2026filed 19 Mar 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 21 Aug 2025filed 25 Aug 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $42K7,037 at $5.93 | filing |
| 20 May 2025filed 22 May 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $29K7,218 at $4.08 | filing |
| 25 Feb 2025filed 27 Feb 2025 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —205,019 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —136,680 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $29K5,171 at $5.62 | filing |
| 20 Nov 2024filed 22 Nov 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $25K5,260 at $4.79 | filing |
| 20 Aug 2024filed 22 Aug 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $31K5,289 at $5.86 | filing |
| 21 May 2024filed 23 May 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $40K5,167 at $7.81 | filing |
| 20 Feb 2024filed 22 Feb 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $47K5,341 at $8.75 | filing |
| 16 Jan 2024filed 18 Jan 2024 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,000 at $0.00 | filing |
| 16 Jan 2024filed 18 Jan 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —127,750 at $0.00 | filing |
| 26 Dec 2023filed 28 Dec 2023 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code M | —75,000 at $0.00 | filing |
| 26 Dec 2023filed 28 Dec 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code M | $74K75,000 at $0.99 | filing |
| 26 Dec 2023filed 28 Dec 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $1.4M225,000 at $6.36 | filing |
| 20 Nov 2023filed 22 Nov 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $13K2,873 at $4.36 | filing |
| 21 Aug 2023filed 23 Aug 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $10K2,884 at $3.55 | filing |
| 23 May 2023filed 25 May 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $10K2,873 at $3.65 | filing |
| 21 Feb 2023filed 24 Feb 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $10K3,439 at $3.00 | filing |
News
November 16, 2026 Deadline: Join Class Action Lawsuit Against Ardelyx, ...ARDX · pr-inside.com · 20 Oct 2026ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStARDX · prnewswire.com · 15 Oct 2026ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your LossesARDX · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Justin A. Renz; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.